Neil Spector

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Oncogene · 2002 · Last of 9 authors · 546 citations

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily…

Journal of Clinical Oncology · 2005 · Last of 16 authors · 500 citations